Inhibrx Biosciences provided updates on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda for head and neck squamous cell carcinoma and non-small cell lung cancer.
Expansion cohorts of ozekibart are being investigated in late-line colorectal cancer and refractory Ewing sarcoma.
Expectations for trial completion and data maturity timelines were highlighted.
INBRX-106 Trial Progress
Enrollment ongoing, expected completion in Q1 2026, primary endpoint on overall response rate.
Ozekibart Expansion Cohorts
Encouraging responses observed in FOLFIRI combination for colorectal cancer, plans for accelerated FDA discussion in 2026.
Data Maturity Timing
Maturity expected in the second half of 2026 for comprehensive program efficacy evaluation.
- The progress updates reveal promising developments in targeting advanced cancers with innovative therapies.
- Potential advancements in treatment strategies for challenging tumors may impact the future standard of care.
- Clinical trial timelines and milestones provide insights into the trajectory of the company's research programs.
Inhibrx Biosciences continues to advance its therapeutic programs with optimism for potential clinical benefits in challenging oncology indications. The upcoming data milestones in 2026 are crucial for evaluating program efficacy and regulatory pathways.